Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Topoisomerase IIalpha controls the decatenation checkpoint.

Literature DB >> 19098900

Topoisomerase IIalpha controls the decatenation checkpoint.

Kuntian Luo¹, Jian Yuan, Junjie Chen, Zhenkun Lou.

Abstract

Topoisomerase II (Topo II) is required to separate intertwined sister chromatids before chromosome segregation can occur in mitosis. However, it remains to be resolved whether Topo II has any role in checkpoint control. Here we report that when phosphorylated, Ser 1524 of Topo IIalpha acts as a binding site for the BRCT domain of MDC1 (mediator of DNA damage checkpoint protein-1), thereby recruiting MDC1 to chromatin. Although Topo IIalpha-MDC1 interaction is not required for checkpoint activation induced by DNA damage, it is required for activation of the decatenation checkpoint. Mutation of Ser 1524 results in a defective decatenation checkpoint. These results reveal an important role of Topo II in checkpoint activation and in the maintenance of genomic stability.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2008 PMID： 19098900 PMCID： PMC2712943 DOI： 10.1038/ncb1828

Source DB: PubMed Journal: Nat Cell Biol ISSN： 1465-7392 Impact factor: 28.824

30 in total

1. Cell cycle checkpoint function in bladder cancer.

Authors: Sharon C Doherty; Stephanie R McKeown; Valerie McKelvey-Martin; C Stephen Downes; Anthony Atala; James J Yoo; Dennis A Simpson; William K Kaufmann
Journal: J Natl Cancer Inst Date: 2003-12-17 Impact factor: 13.506

2. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage.

Authors: C Holm; T Stearns; D Botstein
Journal: Mol Cell Biol Date: 1989-01 Impact factor: 4.272

Review 3. Coming undone: how to untangle a chromosome.

Authors: C Holm
Journal: Cell Date: 1994-07-01 Impact factor: 41.582

4. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.

Authors: C S Downes; D J Clarke; A M Mullinger; J F Giménez-Abián; A M Creighton; R T Johnson
Journal: Nature Date: 1994-12-01 Impact factor: 49.962

5. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.

Authors: P Ackerman; C V Glover; N Osheroff
Journal: Proc Natl Acad Sci U S A Date: 1985-05 Impact factor: 11.205

6. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro.

Authors: N J Wells; C M Addison; A M Fry; R Ganapathi; I D Hickson
Journal: J Biol Chem Date: 1994-11-25 Impact factor: 5.157

7. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.

Authors: Taku Nakagawa; Yoji Hayashita; Ken Maeno; Akira Masuda; Nobuyoshi Sugito; Hirotaka Osada; Kiyoshi Yanagisawa; Hiromichi Ebi; Kaoru Shimokata; Takashi Takahashi
Journal: Cancer Res Date: 2004-07-15 Impact factor: 12.701

8. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

Authors: Isaac A Manke; Drew M Lowery; Anhco Nguyen; Michael B Yaffe
Journal: Science Date: 2003-10-24 Impact factor: 47.728

9. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.

Authors: J Roca; R Ishida; J M Berger; T Andoh; J C Wang
Journal: Proc Natl Acad Sci U S A Date: 1994-03-01 Impact factor: 11.205

10. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks.

Authors: D J Clarke; R T Johnson; C S Downes
Journal: J Cell Sci Date: 1993-06 Impact factor: 5.285

50 in total

1. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.

Authors: Catherine J Drummond; Graeme J Finlay; Laura Broome; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Journal: Invest New Drugs Date: 2010-06-22 Impact factor: 3.850

Topoisomerase IIalpha controls the decatenation checkpoint.

1. Cell cycle checkpoint function in bladder cancer.

2. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage.

Review 3. Coming undone: how to untangle a chromosome.

4. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.

5. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.

6. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro.

7. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.

8. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

9. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.

10. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks.

1. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.

2. Novel kinetochore function of Topoisomerase IIα.

3. MCPH1 is essential for cellular adaptation to the G₂-phase decatenation checkpoint.

4. Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells.

Review 5. DNA repair and personalized breast cancer therapy.

Review 6. Targeting DNA topoisomerase II in cancer chemotherapy.

7. A Role for the Twins Protein Phosphatase (PP2A-B55) in the Maintenance of Drosophila Genome Integrity.

Review 8. MDC1: The art of keeping things in focus.

9. A divergent role of the SIRT1-TopBP1 axis in regulating metabolic checkpoint and DNA damage checkpoint.

10. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.